In a report published Friday, Canaccord Genuity reiterated its Hold rating on AngioDynamics ANGO, but slightly lowered its price target from $12.50 to $11.50.
Canaccord Genuity noted, “Coming out of ANGO's January analyst meeting, we expressed skepticism about growth prospects for the company's products – namely in Peripheral Vascular, Fluid Management and Access – given the sluggish growth dynamics in these markets. While some products (e.g. BioFlo) have more attractive growth prospects than others; overall we do not foresee consistent double-digit growth potential from existing businesses.”
AngioDynamics closed on Thursday at $12.58.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in